Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Signs at AMPAC Fine Chemicals' location in the Petersburg Industrial Park have already been changed to 'Novo Nordisk' in advance of the acquisition ...

Biocon and Zentiva receive EU approval for generic versions of Victoza (diabetes) and Saxenda (weight management). This marks ...

Novo Holdings has completed the previously announced acquisition of Catalent in an all-cash transaction valued at around $16.5bn.

Novo Nordisk's CargiSema Phase III trial showed significant weight loss but failed reach ambitious targets set by management.

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European Commission (EC) gave its approval in early December 2024. Catalent's ...

Catalent to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership Catalent ... following the completion of the transaction, Novo ...

Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion ...

The latest announcement is out from Catalent ( (CTLT) ).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...